Video Shorts

Maintenance therapy with Midostaurin in AML patients with FLT3 mutations has shown potential in improving event-free survival and reducing relapse risk.

Iron chelation therapy (ICT) in MDS is used to manage iron overload from frequent blood transfusions. It involves identifying patients who would benefit most, monitoring iron levels, and managing side effects of chelators

Several studies carried out by institutions of repute have shown that Dasatinib 50 mg is as effective as 100 mg with less side effects.

High risk disease is observed in 30% of Myeloma Cases. Identification of high-risk patients is important as proportion of high-risk cases increase with relapses and can lead to significant mortality.

Metastatic Triple Negative Breast Cancer is still an unmet medical need.

For relapsed and refractory multiple myeloma, use of pomalidomide often in combination with dexamethasone or other agents is recommended in patients who have failed at least two prior treatments, including lenalidomide and a proteasome inhibitor.

Whole Genome Sequencing (Short)
Whole Genome Sequencing is new tool for precision medicine in metastatic castration

Need to maximise the response to hypomethylating agents: Standard of care for high-risk Myelodysplastic Syndromes is Hypomethylating agents. Average time to response is about 3 months with either Azacytidine or Decitabine.

ASCO GU 2022 had 4 important clinical trials in prostate cancer discussed in plenary session as follows.

Myelodysplastic Syndromes (MDS) or Myeloproliferative Neoplasms show considerable heterogeneity with respect to presence of anemia , cytopenia & molecular features.